Economic aspects of second generation insulin analogs in diabetes mellitus type 2
https://doi.org/10.24411/2588-0519-2019-10053
Abstract
Th e comparison of economic parameters of insulin glargine 300 UI/ml (GLA-300) and insulin degludec 100 UI/ml (DEG-100) has been performed based on data of the direct comparison in BRIGHT trial and real world evidences (published and data of the Federal Register of Diabetes without personal data of patients). Direct cost for medications calculated according to daily doses of insulins and duration of treatment as well as of cost of hypoglycemic events. Estimations based on BRIGHT trial shown direct cost for DEG-100 treatment higher than for GLA-300 on 77,3% due to less cost of 1 UI of GLA-300. Hypoglycemic events rate was equal in both groups and they cost did not include into analysis. GLA-300 can be used in 158 pts if fi nance, which allocated for a treatment of 100 pts by DEG-100 will transfer for GLA-300. Economic advantages of GLA-300 are confi rmed by calculations of direct costs as well as cost/eff ective ratio in real world data collection. Cost of less hypoglycemic events in DEG-100 treatment demonstrated in some real world evidences does not compensate much higher expenditures in comparison with GLA-300 treatment. Th erapy with DEG-100 more costly on 43,6-55,2 % (depending of type of analysis). Further analysis of GLA-300 and DEG-100 economics is needed for better decision makes in state purchases.
About the Authors
Dmitry Yurievich Belousov
http://www.healtheconomics.ru/
ООО "Центр фармакоэкономических исследований", г. Москва
Russian Federation
ООО "Центр фармакоэкономических исследований", г. Москва
Russian Federation
General Director of LLC "Center for Pharmacoeconomics
Research"
Oleg Karpov
JSC "Sanofi Russia"
Russian Federation
MD, professor, employee of JSC "Sanofi Russia", the head of the group on the Economics of healthcare
Russian Federation
MD, professor, employee of JSC "Sanofi Russia", the head of the group on the Economics of healthcare
References
1. URL: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes, (дата обращения 16.01.2019).
2. Dedov II, Kalashnikova MF, Belousov DY. Diabetes Mellitus. 2016;19(6):518-527. (In Russ).
3. Dedov II, Kalashnikova MF, Belousov DY. Cost-of-illness analysis of type 2 diabetes mellitus in the Russian Federation: results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (forsight-т2dm). Diabetes Mellitus. 2017;20(6):403–419. (In Russ). DOI: 10.14341/DM9278
4. Kontsevaya A, Karpov O, Shestakova M, Belousov Y. Economic evaluation of diabetes mellitus type 2 burden and it’s main cardiovascular complications in the Russian Federation. Value in Health. 2017;20:A374.
5. Standards of specialized diabetes care. Ed by Dedov II, Shestakova MV, Mayorov AY. 8th Edition. Moscow: UP PRINT; 2017. (In Russ). DOI 10.14341/DM20171S8
6. Nicolucci A, Prosperini G, Buzzetti R, et al. A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes // Minerva Endocrinol. 2018;43(4):501–510. DOI: 10.23736/S0391-1977.18.02850-X.
7. Gregg EW, Sattar N, Ali MK. Th e changing face of diabetes complications. // Lancet Diabetes Endocrinol. 2016;4(6):537–547. DOI: 10.1016/S2213-8587(16)30010-9.
8. Chatterjee S, Khunti K, Davies MJ. Achieving glycaemic control with concentrated insulin in patients with Type 2 Diabetes // Drugs. 2019:1–14 https://doi.org/10.1007/s40265-018-1048-6.
9. Belousov DU, Karpov OI. Evaluation of direct cost in case of insulin GLA-100rgine-100 switching to insulin GLA-100rgine-300 in diabetes mellitus in real clinical practice. Kachestvennaya klinicheskaya praktika. 2017:3:14–15. (In Russ). DOI.org/10.1007/s40265-018-1048-6
10. Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) // Diabetes Care. 2014;37(10):2755–2762. DOI.org/10.2337/dc14-0991
11. Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) // Diabetes Care. 2014;37(12):3235–3243.
12. Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab. 2015;17(4):386–394. DOI: 10.1111/dom.12438
13. Wiesli P, Schories M. Improved glycemic control with insulin glargine 300 U/mL (Toujeo®) in patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland. Diabetes Ther. 2018;9(6):2325-2334. DOI: org/10.6084/m9.fi gshare.7117718
14. Oriot P, Jérémie W, Buysschaert M. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life. Expert Rev Endocrinol Metab. 2018;13(3):167–171. DOI: 10.1080/17446651.2018.1469405
15. Okajima F, Nakamura Y, Yamaguchi Y, et al. Basal-bolus insulin therapy with gla-300 during hospitalization reduces nocturnal hypoglycemia in patients with type 2 diabetes mellitus: a randomized controlled study. Diabetes Ther. 2018;9(3):1049–1059. DOI: 10.1007/s13300-018-0419-z
16. Bonadonna RC, Renard E, Cheng A, et al. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract. 2018;142:19–25. DOI: 10.1016/j.diabres.2018.03.041
17. Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of Insulin Glargine 300 U/mL in people with Type 2 Diabetes. Diabetes Technol Ther. 2016;18(4):252–257. DOI: 10.1089/dia.2015.0290.
18. Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ. 2018;21(2):144–151. DOI: 10.1080/13696998.2017.1384383.
19. Heise T, Nørskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–1039. DOI: 10.1111/dom.12938
20. Kolbin AS, Shestakova MV, Galstyan GR. Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. Problems of Endocrinology. 2017;63(5):307–319. URL: https://doi.org/10.14341/probl2017635307-319.
21. Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/ml versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: Th e Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018;41(10):2147–2154. URL: https://doi.org/10.2337/dc18-0559.
22. Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative eff ectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018;20:2148–2158. DOI. org/10.1111/dom.13345.
23. Tibaldi J, Hadley-Brown M, Leibl A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U/ml in insulin-naïve patients with type 2 diabetes. Diabetes Obes Metab. 2019:1–9. DOI:10.1111/dom.13616
24. URL: http://grls.rosminzdrav.ru (дата обращения 17.01. 2019).
25. Farmakoehkonomika i farmakoehpidemiologiya — praktika priemlemykh reshenij. Red. VB Gerasimov, АL KHokhlov, OI Karpov. — Moscow: Meditsina; 2005. (In Russ).
26. Ametov AS, Nevolnikova AO, Mishra OA, Golubeva LB. Clinical aspects of the use of insulin glargine (300 ED/ml) in patients with type 2 diabetes: from research to outpatient practice. Endocrinology: News, Opinions, Training. 2018;7(3):39–54. (In Russ). DOI: 10.24411/2304-9529-2018-13004
27. Landstedt-Hallin L, Gundgaard J, Ericsson Å, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin. 2017;33(4):647–655. DOI: 10.1080/03007995.2016.1277194
28. Ponzani P, Berra C, Di Lelio A, et al. Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety. Diabetes Ther. 2018;9(6):2209–2218. DOI: 10.1007/s13300-018-0511-4
29. Popovich LD, Potapchik EG, Svetlichnaya SV. Ocenka ehkonomicheskih vygod ot realizacii ehffektivnyh programm bor’by s saharnym diabetom 2-go tipa. Preprint WP8/2018/01. Gosudarstvennoe i municipal’noe upravlenie. Moscow: 2018. (In Russ).
30. Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6(2):e009421. DOI: 10.1136/bmjopen-2015-009421
31. Omelyanovsky VV, Shestakova MV, Avxentyeva MV. The Economic Aspects of Diabetes Mellitus in the National Practice. Medicinskie tekhnologii. Ocenka i vybor. 2015;4(22):43–60. (In Russ).
32. Belousov DU, Afanasyeva EV. Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects. Kachestvennaya klinicheskaya praktika. 2014;1: 3–13. (In Russ).
Review
For citations:
Belousov D.Yu., Karpov O. Economic aspects of second generation insulin analogs in diabetes mellitus type 2. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(1):4-11. (In Russ.) https://doi.org/10.24411/2588-0519-2019-10053
Views:
950
Email this article 